LDL-R depletion also improves the response of cells to gemcitabine and leads to tumor regression, shedding light to not only an appealing target for therapeutic exploitation, but also to a potentially effective way of sensitizing cancer cells to conventional treatment regiments [79]. This evidence concerns the gene LDLR and cancer.